An Open-Label, Randomized Phase III Study of Trastuzumab Rezetecan With or Without Bevacizumab in First to Third Line BLIS Subtype TNBC

This study is a prospective, open-label, phase III, randomized controlled clinical trial. It is planned to screen patients with inoperable locally advanced or metastatic triple-negative breast cancer of the BLIS subtype. A total of 140 patients are planned to be enrolled.

NCT Number	NCT07669610
Lead Sponsor	Fudan University
Conditions	Breast Cancer, Triple Negative Breast Cancer (TNBC)
Enrollment	140 participants
Start Date	2026-10-01
Primary Completion	2028-09-30 (estimated)
Study Completion	2029-03-30 (estimated)
Updated on ClinicalTrials.gov	2026-06-25